Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Irinotecan in Refractory Advanced Colorectal Cancer
NCT00005076Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 1999
- Primary completion
- Jul 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cetuximab in colorectal cancer (CRC), sponsored by University of Alabama at Birmingham. Started Oct 1999; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00005076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005076.